ECB-ART-49030
Lung Cancer
2021 Oct 01;160:32-35. doi: 10.1016/j.lungcan.2021.07.020.
Show Gene links
Show Anatomy links
Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance.
???displayArticle.abstract???
Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown a high response rate and long progression-free survival in primary treatment of ALK-positive non-small-cell lung cancer (NSCLC). De novo resistance or refractory subtype is rare event. Herein, we identify the first case with serial next-generation sequencing (NGS) results that harboured a rare echinoderm microtubule associated protein like 4 gene (EML4) -ALK (breaking site at exon 19) fusion in a lung adenocarcinoma (LUAD) patient who acquired alectinib resistance rapidly (less than 3 months), followed by multi-drug resistance and short survival time.
???displayArticle.pubmedLink??? 34391065
???displayArticle.link??? Lung Cancer